JAK Inhibition With Ruxolitinib Versus Best Available Therapy for Myelofibrosis

New England Journal of Medicine- United States

doi 10.1056/nejmoa1110556

Full Text

Abstract

Available in

Categories

Date

March 1, 2012

Authors

Claire Harrison

Jean-Jacques Kiladjian

Haifa Kathrin Al-Ali

Heinz Gisslinger

Viktoriya Stalbovskaya

Deborah S. Hunter

Francisco Cervantes

Alessandro M. Vannucchi

Giovanni Barosi

Publisher

Massachusetts Medical Society

Related search

Cost-Effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain

Journal of Health Economics and Outcomes Research

English

Primary Myelofibrosis Associated Glomerulopathy: Significant Improvement After Therapy With Ruxolitinib

English

Efficacy of Ruxolitinib for Myelofibrosis

Expert Opinion on Pharmacotherapy

English

Ruxolitinib for Myelofibrosis–An Update of Its Clinical Effects

Clinical Lymphoma, Myeloma and Leukemia

Cancer Research

English

Ruxolitinib as an Emerging Treatment in Myelofibrosis

Blood and Lymphatic Cancer: Targets and Therapy

English

Placebo Versus Best-Available-Therapy Control Group in Clinical Trials for Pharmacologic Therapies: Which Is Better?

Proceedings of the American Thoracic Society

English

Definition and Management of Ruxolitinib Treatment Failure in Myelofibrosis

Blood Cancer Journal

English

Sweet Syndrome Successfully Treated With Ruxolitinib in JAK-2 Positive Myeloproliferative Disorder

English

Safety and Efficacy of Ruxolitinib in Myelofibrosis Patients Without Splenomegaly

British Journal of Haematology

English